Analysis of Medication Utilization in Isolated Areas of Fever Clinics During the COVID-19 Epidemic Outbreak: A Multicenter Study in General Hospitals in China

Author:

Zhang Zhiqing1,Zang Yaru2,Yang Jingyi3,Yang Kaining4,Zhao Yue5,Zhang Wei6,Guo Shuanghu7,Han Chaoxu8,Liu Chaoxing9,Mi Xiangzheng10,Wang Xiaoli11,Wang Chuanping1

Affiliation:

1. Second Hospital of Hebei Medical University

2. Affiliated Hospital of Chengde Medical College

3. First Hospital of Qinhuangdao

4. Baoding Second Central Hospital

5. Sanhe City Hospital in Hebei Province

6. Qian'an People's Hospital

7. Affiliated Hospital of Hebei Engineering University

8. Handan Central Hospital

9. Xingtai Ninth Hospital

10. Gucheng Country Hospital

11. Nanpi Country People's Hospital

Abstract

Abstract

Objective: To analyze the demographic characteristics and patterns of medication use among patients in fever clinics (FCs) during the COVID-19 outbreak in China and provide information for COVID-19 treatment. Method: Various-grade general hospitals in China were selected, and patient information was extracted during the initial wave of the COVID-19 epidemic. Demographic characteristics were analyzed, including visit time, age, sampling morbidity rate, and disease distribution. Prescription information from the FC database was extracted to analyze drug use and the rationality of the medication. Result: Between September 1 and December 31, 2022, 41,445 patients received treatment at FCs in 11 included hospitals. After the relaxation of COVID-19 control measures, there was a rapid increase in the number of daily patient visits (peaking >1,000 people/day, with a growth rate of 158.8%). The highest sampling morbidity rate was observed among individuals over 85 years old (>100 person-times/million population), followed by children (60-94 person-times/million population). Respiratory system diseases (39,295 cases) were the most diagnosed, with respiratory system infections (21,201 cases) and fever (15,132 cases) the most common. The proportion and frequency of use of essential national drugs were 34.3% and 73.1%, respectively, while those for the drugs recommended in the national COVID-19 treatment guidelines were 6.1% and 43.2%, respectively. Ibuprofen, acetaminophen, and Lianhua Qingwen had the highest frequency of drug use. The most prescribed drugs by cost were immunoglobulin, azivudine, and cefoperazone sulbactam. The water-electrolyte balance regulator drugs, respiratory system drugs, anti-infective drugs, and traditional Chinese patent drugs were the most frequently used. In contrast, immunomodulators, anti-infectives, and Chinese patent drugs had the largest monetary amounts. There was a significant difference in medication rationality between different hospital grades (P<0.001), with tertiary teaching hospitals having the highest rate. Conclusion: Strict epidemic control measures and the role of FCs played a crucial role in controlling the spread of the COVID-19 epidemic. Patients treated in FCs predominantly suffered from respiratory diseases, with older patients and children identified as high-risk populations. Physicians often choose national guidelines, essential drugs, and traditional Chinese for COVID-19 treatment. Tertiary teaching hospitals played a crucial role during the epidemic outbreak.

Publisher

Springer Science and Business Media LLC

Reference46 articles.

1. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization. (https //covid19. who. int/table).

2. Early remdesivir to prevent progression to severe Covid-19 in outpatients;Gottlieb RL;N Engl J Med,2022

3. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention;Wu Z;JAMA,2020

4. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy;Onder G;JAMA,2020

5. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK;Docherty AB;Lancet Respir Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3